Pharma News

ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today announced it has agreed to purchase Bristol-Myers Squibb’s late stage HIV R&D assets. In a separate deal, ViiV Healthcare has agreed to acquire Bristol-Myers Squibb’s HIV portfolio of pre-clinical and discovery stage research assets. Each deal is subject to clearance by the regulatory authorities and is expected to complete in early 2016.

A researcher from George Washington University is exploring the possibility of using a new technique for human reproduction and its ethical and practical implications.

[adsense:336x280:8701650588]

Chronic alcohol use, when combined with repeated binge drinking, causes more damage to the liver than previously thought, says an Indian-origin researcher from University of Missouri-Columbia.

Gene variants linked to cell senescence or biological ageing, autoimmunity, and Alzheimer's disease play an important role in determining whether we would live over 100 years or not, new research has found.

A diet high on fat but very low on carbohydrates which is generally favoured by body-builders may be effective in treating schizophrenia, new research has found.

A drug currently used to treat patients with osteoporosis can protect stem cells from ageing, a breakthrough study has found.

Sanofi and Boehringer Ingelheim have entered into exclusive negotiations to swap businesses. The proposed transaction would consist of an exchange of Sanofi animal health business (Merial) with an enterprise value of €11.4 billion and Boehringer Ingelheim consumer healthcare (CHC) business with an enterprise value of €6.7 billion. Boehringer Ingelheim CHC business in China would be excluded from the transaction. The transaction would also include a gross cash payment from Boehringer Ingelheim to Sanofi of €4.7 billion.

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced a collaboration agreement with Teva Pharmaceutical Industries Ltd. ("Teva"), a leading global pharmaceutical company. With this agreement, Egalet granted Teva exclusive marketing and commercialization rights to SPRIX (ketorolac tromethamine) Nasal Spray in Israel, Gaza and the West Bank. Teva, a leader in the commercialization of central nervous system (CNS) products, including many in pain management, will be responsible for registering, marketing, distributing and selling SPRIX Nasal Spray in these territories. Under the terms of the agreement, Egalet will receive an undisclosed upfront payment, sales-based milestones and will share in the profits from net sales of SPRIX in these territories. 

Heart disease and stroke were the number one and number two killers worldwide in 2013, reveals a new report.